B2B; AI; Biotech; SaaS
Amby Health
Agents for Accelerated Clinical Trial Design
Winter 2025
Emily Nieves
Co-Founder & CEO
Emily Nieves MIT PhD candidate in Biological Engineering with prior computational/pharma experience (Pfizer AstraZeneca); focuses on scientific ML and systems pharmacology. Jawad Iqbal Co-founder & CTO with a Masters in Mechatronics/Robotics background in robotics/AI and systems integration prior work at Lockheed Martin.
Total Raised
$500K
Stage
Early
Latest Round
Pre-seed
Industry
B2B; AI; Biotech; SaaS
About
Delineate is building AI agents to design better clinical trials faster.
This is a $10B dollar market where saving even 1 day along the process is equal to $1-5M in revenue potential.
We process existing clinical trial research into specialized datasets saving scientists months of effort.
Delineate is working with two of the largest pharmaceutical companies. With one of our customers we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Key Investors
Y Combinator Unpopular Ventures
Company Snapshot
Employee Count
20
Status
Active
Tags
SaaS Biotech AI
Get Access Now
Automatic workflows, data enrichment, to help you move forward faster.